



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: January 30, 2009

To: Primary Clinical Research Associates

From: Janis Wobschall
Research Protocol Specialist

Re: N0779, Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib
PS-341) in Patients with Recurrent Glioblastoma Multiforme

The Evaluation/Treatment Form (Arm B – Cycle 1) has been revised to reflect a new section to collect surgery information as follows: “One of the stopping rules is a delay in surgery.”

If you have any questions, please feel free to contact me.

Enclosure